MAY-HEALTH
May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it is changing its name from AblaCare to May Health, and has solidified its executive team with Anne Morrissey as CEO and Dr. Robert Auerbach, OBGYN, as chairman of the board. Morrissey, an experienced executive who was previously CEO of Alydia Health, will lead May Health as it investigates its novel Ovarian Rebalancing™ technology, a one-time, transvaginal ablation procedure designed to activate natural ovulation for those with PCOS, a leading cause of infertility.
“With Anne and Bob, May Health is guided by some of the most respected and accomplished leaders in the women's health care ecosystem,” said Antoine Papiernik, chairman and managing partner at Sofinnova Partners, and the previous chairman of May Health. “Anne is an experienced executive and team builder who has devoted her career to making pregnancy and childbirth safer and more accessible. As an OBGYN and retired president of CooperSurgical, Bob brings both clinical and operational expertise to the board. With their leadership, May Health is well positioned to enter a new phase of growth to develop and commercialize life-changing solutions for those living with PCOS.”
May Health’s proprietary technology, Ovarian Rebalancing, is an investigational treatment designed to start a woman’s natural ovulation cycle, allowing for the opportunity to become pregnant. It is an ultrasound-guided, transvaginal ablation procedure similar to egg retrieval that utilizes radiofrequency (RF) energy to establish regular menstrual cycles. Ovarian Rebalancing is a one-time, in-office procedure intended to allow for same-day recovery and return to normal activities. It is currently being investigated in a European clinical study and a U.S. feasibility study.
“Those with PCOS face significant health challenges and frustrations every day, from symptoms like weight gain and acne to irregular menstrual cycles and life-altering complications around ovulation and fertility,” said Dr. Auerbach. “The current fertility treatment landscape can be just as distressing for patients with concerns regarding cost, access, and the complexity of in vitro fertilization (IVF), along with side-effects of gonadotropins. Our goal is to develop a safe, simple procedure that activates natural ovulation for women living with PCOS. Ovarian Rebalancing has the potential to fill that need and help thousands of women regain the option to have children and start families, and we look forward to continuing to enroll patients in our clinical trials to demonstrate these benefits.”
“I joined May Health to change the outlook for people living and struggling with the negative effects of PCOS,” said Morrissey. “Restoring ovulation is our current focus, but our technology may also have the potential to address the underlying endocrine disorder. Our new name reflects this overarching commitment to helping women overcome PCOS and experience new beginnings and opportunities. I’m excited to lead and build a team that has the experience, passion, and empathy needed to improve the PCOS outlook for millions of women.”
About Polycystic ovary syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is a common endocrine condition where the ovaries produce abnormal levels of androgens, which are male sex hormones that are usually present in women in small amounts.1 In many cases, those with PCOS are unable to produce enough of the hormones needed to ovulate and become pregnant, which can lead to the development of ovarian cysts.1 PCOS is one of the most common causes of female infertility, affecting roughly 6 to 12% of U.S. women of reproductive age.2 PCOS is also a lifelong challenge that goes beyond fertility issues. Women with PCOS are often insulin resistant, increasing their risk for Type 2 diabetes; more than half of PCOS sufferers will develop Type 2 diabetes by age 40 and they are also at increased risk of heart disease and stroke.2 Other common, persistent symptoms of PCOS include irregular menstruation, acne, thinning scalp, excess hair growth on the face and body, high blood pressure, and sleep apnea.2
About Anne Morrissey
Anne Morrissey is an experienced entrepreneur, executive, and advisor who has led numerous medical device companies dedicated to women’s and maternal health care. Anne’s lifelong passion for making childbirth and motherhood safer and more accessible has led to leadership and advisory roles in numerous companies. She is the former Chair, President and CEO of Alydia Health, and serves as director of Femasys Inc.; she previously served as vice president of Astia; as co-founder and director of Vivant Medical; and as entrepreneur in residence of UCSF Innovation Ventures. Anne is a gifted team builder and manager who has led various exits, transitions, and global partnerships; she is an advisor to several prominent medtech CEOs and was named one of the 100 Women of MedTech in 2019.
About Dr. Robert Auerbach
Dr. Robert “Bob” Auerbach, OBGYN, has exemplified commitment to women’s and maternal health over a distinguished 35+ year career that includes both clinical practice and extensive experience running large healthcare companies. Dr. Auerbach served as the chief medical officer, chief strategy officer, and ultimately president of CooperSurgical, a wholly owned subsidiary of The Cooper Companies specializing in women’s healthcare and fertility treatments. He serves as the chairman of the board for Escala Medical, and as a board member for OCON Healthcare, Aspira Women’s Health, Empress Medical, and the Yale University Center for Biomedical Innovation and Technology. Dr. Auerbach is a graduate of the Lehigh-Hahnemann/Drexel 6-year BA-MD program and completed his OB/GYN residency at Yale, where he currently serves as an adjunct member of the medical school faculty.
About May Health
May Health, formerly AblaCare, is a clinical-stage medical device company committed to developing more treatment options for people living with PCOS. The company is currently investigating its Ovarian Rebalancing™ technology in clinical studies; Ovarian Rebalancing is a novel approach to PCOS-related fertility issues that has the potential to be a safe, relatively simple option for activating natural ovulation. May Health is led by a team of serial medtech and women’s health entrepreneurs and executives with extensive experience in product development, validation, and launch. The company has raised €10M in a Series A led by Sofinnova Partners and was founded in 2017 by the firm’s medtech acceleration team, Sofinnova MD Start. May Health is headquartered in Paris, France. For more information, visit www.mayhealth.com.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, visit: sofinnovapartners.com.
____________________
1 Johns Hopkins Medicine
2 CDC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified Lesions5.11.2025 16:12:00 CET | Press release
SIS Medical AG, a Swiss manufacturer of the Super-High-Pressure PTCA balloon catheter (OPN NC), is pleased to announce that the results of the investigator-initiated VICTORY trial were presented during the late-breaking clinical session at TCT 2025 by the Cardiovascular Research Foundation (CRF). The randomized, multi-center clinical study was designed to compare the safety and efficacy between the OPN and IVL devices for lesion preparation and optimized stent expansion in highly complex calcified coronary lesions, deploying a drug-eluting stent (DES). Coronary artery calcium affects approximately one-third of patients undergoing PCI and is a key contributor to procedural and stent failure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105812157/en/ "With a similar safety profile, OPN can be a feasible and faster alternative to IVL." Dr. M. Bossard, Senior Physician at Luzerner Kantonsspital, Switzerland A total of 282 p
Doha Debates Explores the Role of Ancient Wisdom in Today’s World5.11.2025 16:06:00 CET | Press release
Experts and students debate whether ancient wisdom holds answers for modern societies As the world grapples with questions of meaning and moral direction, Doha Debates takes on a fundamental question: Should ancient wisdom guide today’s societies? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105183709/en/ Guest speakers and participating students gather on the Doha Debates stage to discuss a fundamental question “Should ancient wisdom guide today’s societies?” — part of the show’s exploration of timeless questions shaping our world today. (Photo: AETOSWire) In this episode of the new flagship season, moderated by Dareen Abughaida, students from across Qatar join three global thinkers to wrestle with a timeless dilemma: whether the answers to our most pressing problems lie in tradition or in bold new ideas. Wael Hallaq, Avalon Foundation Professor in the Humanities at Columbia University, critiques what he calls the “mor
Versa Delivers Proven Firewall Performance and Security Effectiveness Validated by Independent Testing5.11.2025 15:30:00 CET | Press release
Versa One of Only Three Recommended Products, Maintaining Position as Performance Leader by Delivering Fastest Throughput While Achieving a 99.43% Security Effectiveness Score Versa, the global leader in unified networking and security, today announced that its Next-Generation Firewall received CyberRatings.org’s highest “Recommended” rating for the ninth consecutive year. In the newly published Q3 2025 Enterprise Firewall report, based on independent testing by NSS Labs, Versa delivered 100% scores in critical categories like malware and exploit evasion resistance, and achieved a leading 7,626 Mbps rated throughput, over twice as fast as competing solutions. Selecting cybersecurity solutions requires unbiased, real-world performance testing and evaluation. CyberRatings.org provides IT and security leaders with data-driven results to guide investment decisions. In this latest assessment, Versa ranked among the top three vendors for Security Effectiveness and delivered more than twice t
Its Global Vision on Show, TVS Motor Company Makes a Stellar Debut at EICMA5.11.2025 15:16:00 CET | Press release
Six new products - a resurgent “new Norton”, connected technology, AR based Heads-Up Display Helmets, new range of accessories and a roadmap for Europe - underline TVSM’s presence at the world’s largest 2-wheeler exhibition. TVS Motor Company (TVSM) - a global leader in two and three-wheeler manufacturing - has taken centerstage at EICMA 2025, making a landmark debut at the world’s largest motorcycle exhibition. With a show floor commanding presence, TVS unveiled 6 new products across ICE and thermal powertrains, advanced ride assist gear including AR based Heads-Up display helmets, a stunning new range of accessories, connected technology that enhances rider-machine connect and its roadmap for expansion in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105242034/en/ TVS top leadership team posing with the global showcases at EICMA. From L to R: TVS M1-S, TVS X, TVS eFX three O, TVS RTX 300 and RTX 300 BTO, TVS Ta
Car Connectivity Consortium Releases Inaugural Industry Report on Global Vehicle Connectivity Trends5.11.2025 15:00:00 CET | Press release
60% of industry leaders cite security and ease of use as top priorities in CCC’s new report highlighting global trends and innovation across the connected vehicle ecosystem The Car Connectivity Consortium® (CCC), the trusted source for defining how vehicles interact with devices and the world to enhance the consumer experience through standardized, secure, and convenient connectivity solutions, today released its 2025 Future of Vehicle Connectivity Report. The findings reveal how automakers, suppliers, and technology providers across regions are aligning around secure, seamless connectivity as a foundation for innovation. With Deloitte projecting the value of software-defined vehicles to reach up to $600 billion by 2030, the connected vehicle market is entering a new phase of growth. To better understand how the industry is preparing for this evolution, the CCC surveyed its membership to uncover where companies are investing and focusing their attention. CCC’s more than 300 member comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom